Reuters
Individual Analyses of Bias in Reuters Articles
In addition to conducting full-scale reviews of media outlets for overall bias — using methodologies such as Blind Bias Surveys and Editorial Reviews — AllSides sometimes evaluates the bias of an individual news article for bias.
The AllSides editorial team has detected common types of media bias in some individual Reuters articles, including word choice bias, bias by placement, slant, and spin. Read our analysis of each story on the AllSides Perspectives blog:
Type of Content
Approved Story
1
Format
Region
News Item Format
Standard
Image Caption
REUTERS/Hannah Beier/File Photo
June 28 (Reuters) - Advisers to the U.S. Food and Drug Administration on Tuesday recommended a change in the design of COVID-19 booster shots this fall in order to combat more recently circulating variants of the coronavirus.
The FDA's Vaccines and Related Biological Products Advisory Committee voted 19-2 that the next wave of COVID booster shots should include a component that targets the Omicron variant of the coronavirus.
The FDA plans to decide by early July on what the design of the boosters should be.
FDA scientists at the meeting suggested they preferred vaccines that will target the BA.4 and BA.5 Omicron subvariants that are currently dominant rather than the BA.1 Omicron variant that led to a massive surge in infections last winter.
Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said the regulator would hope to launch a booster campaign with a retooled vaccine by October.
"The better the match of the vaccines to the circulating strain we believe may correspond to improved vaccine effectiveness, and potentially to a better durability of protection," Marks told the meeting of outside expert advisers to the agency.
Pfizer Inc (PFE.N), Moderna Inc (MRNA.O) and Novavax Inc (NVAX.O) presented data at the meeting. All three companies have been testing versions of their vaccines updated to combat the BA.1 Omicron variant.